Gene therapy - The gutless approach pays off

Trends in Genetics

Volumn 14, Issue 4, 1998, Pages 136-137

  Whittle, Nigel ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID DNA; VASCULOTROPIN; VIRUS VECTOR;

CONFERENCE PAPER; ENZYME DEFICIENCY; GENE THERAPY; GENE TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROVIRUS;

EID: 0031955604     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-9525(98)01439-5     Document Type: Conference Paper

References (5)

1. Orkin, S.H. and Motulsky, A.G. (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy, NIH press.
2. Parks R.J.et al. Proc. Natl. Acad. Sci. U. S. A. 93:1996;13565-13570.
3. Breakefield, X.O. et al. (1995) in The Internet Book of Gene Therapy, Appleton and Lange.
4. Paillard F. Hum. Gene Ther. 8:1997;1733-1735.
5. Isner J.M.et al. Lancet. 348:1996;370-374.